Match!
Elsa Vieira-Sousa
Instituto de Medicina Molecular
Physical therapyPsoriatic arthritisRheumatoid arthritisDiabetes mellitusMedicine
77Publications
10H-index
427Citations
What is this?
Publications 81
Newest
#1Elsa Vieira-Sousa (IMM: Instituto de Medicina Molecular)H-Index: 10
#2Pedro AlvesH-Index: 3
Last. R. AguiarH-Index: 1
view all 24 authors...
Objectives To assess the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy in psoriatic arthritis (PsA) dactylitis. Methods Multicentre, investigator-initiated, randomised, double-blind, placebo-controlled, parallel-design phase 3b trial in 11 Portuguese rheumatology centres. Patients with PsA along with active dactylitis and naive to MTX and biologic disease-modifying antirheumatic drugs (bDMARDs) were randomly assigned to golimumab or placebo, both in combinat...
Source
Source
#1Brigitte Michelsen (Hospital of Southern Norway)H-Index: 5
Last. Ziga RotarH-Index: 7
view all 31 authors...
OBJECTIVES: To assess the impact of 'patient's minus evaluator's global assessment of disease activity' (DeltaPEG) at treatment initiation on retention and remission rates of TNF inhibitors (TNFi) in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients across Europe. METHODS: Real-life data from PsA and axSpA patients starting their first TNFi from 11 countries in the European Spondyloarthritis Research Collaboration Network were pooled. Retention rates were compared by Kaplan-...
Source
#2Alexandre SeprianoH-Index: 13
Last. Vinagre FH-Index: 5
view all 20 authors...
Objectives To compare definitions of high disease activity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in selecting patients for treatment with biologic disease-modifying antirheumatic drugs (bDMARDs). Methods Patients from Rheumatic Diseases Portuguese Register (Reuma.pt) with a clinical diagnosis of axial spondyloarthritis (axSpA) were included. Four subgroups (cross-tabulation between ASDAS (≥2.1) and BASDAI (≥4)...
Source
#1Santiago Rodrigues-Manica (NSU: Nova Southeastern University)
#2Alexandre Sepriano (LEI: Leiden University)H-Index: 13
view all 17 authors...
#1Vasco C. Romão (IMM: Instituto de Medicina Molecular)H-Index: 10
#2Joaquim Polido-Pereira (IMM: Instituto de Medicina Molecular)H-Index: 11
Last. João Eurico Fonseca (IMM: Instituto de Medicina Molecular)H-Index: 32
view all 12 authors...
Source
#1Elsa Vieira-SousaH-Index: 10
#2M EusébioH-Index: 5
Last. Maria José SantosH-Index: 24
view all 18 authors...
Objective To assess long-term effectiveness of tumor necrosis factor inhibitors (TNFi) in psoriatic arthritis (PsA) patients registered in the Rheumatic Diseases Portuguese Register, exposed to at least one TNFi, prospectively followed between 2001-2017. Methods Kaplan-Meier analysis was performed for first-, second-, and third-line TNFi. Response included European League Against Rheumatism (EULAR), Disease Activity Index for Psoriatic Arthritis (DAPSA), Minimal Disease Activity (MDA), and Ankyl...
Source
Source
#1P. Ávila-Ribeiro (IMM: Instituto de Medicina Molecular)H-Index: 3
#2João Eurico Fonseca (IMM: Instituto de Medicina Molecular)H-Index: 32
Last. Elsa Vieira-Sousa (IMM: Instituto de Medicina Molecular)H-Index: 10
view all 3 authors...
Background Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) under biologic treatment are increasingly achieving prolonged remission and tapering treatment is becoming standard practice. However, the optimal timing to start tapering remains unclear and predictors of loss of remission (LOR) are missing. Guidelines disagree on whether to wait for 6 or 12 months of sustained remission before tapering. Objectives To determine whether longer sustai...
Source
#1Elsa Vieira-SousaH-Index: 10
#2M EusébioH-Index: 5
Last. Maria José SantosH-Index: 24
view all 18 authors...
Background: The impact of gender on tumor necrosis factor inhibitors (TNFi) effectiveness has been poorly studied in Psoriatic Arthritis (PsA) patients. Objectives: To study gender differences in persistence and response of 1st TNFi in PsA patients. Methods: PsA patients prospectively followed at the Rheumatic Diseases Portuguese Registry (Reuma.pt), treated with a 1st TNFi, between 2001 and 2016. Drug retention assessed by Kaplan-Meier survival analysis and Cox models, adjusted for the year of ...
Source
123456789